

innate pharma

Q3 2023 Financial Results and Business Update

14 November 2023

EURONEXT : IPH.PA NASDAQ : IPHA

Disclaimer on Forward-Looking Information and Risk Factors

This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed.

This document contains forward-looking statements. The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to various risks and uncertainties, which could cause the Company’s actual results or financial condition to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Universal Registration Document filed with the Autorité des Marchés Financiers (“AMF”), available on the AMF website (www.amf-france.org) or on the Company’s website (www.innate-pharma.com), and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20F for the year ended December 31, 2022, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company. Such documents may not be necessarily up to date.

This document contains data pertaining to the Company's potential markets and the industry and environment in which it operates. Some of this data comes from external sources that are recognized in the field or from Company’s estimates based on such sources.

This presentation discusses product candidates that are under clinical development, and which have not yet been approved for marketing by the U.S. Food and Drug Administration or the European Medicines Agency. No representation is made as to the safety or effectiveness of these product candidates for the use for which such product candidates are being studied.

The information contained herein has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. The Company is under no obligation to keep current the information contained in this presentation and any opinion expressed is subject to change without notice.

The Company shall not bear any liability whatsoever for any loss arising from any use of this document or its contents or otherwise arising in connection therewith.

This document and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares of the Company in any country.

innate pharma

Speakers on Today's Call



Mondher Mahjoubi
MD

Chief Executive Officer

Chairman of the Executive Board



Sonia Quaratino
MD

Chief Medical Officer



Yannis Morel
PhD

Head of Business Development and Product Portfolio Strategy



Frédéric Lombard
MBA

Chief Financial Officer

innate pharma

Scientific innovation drives our strategy







Our ambition –
leverage our scientific know-how in innate immunity and antibody engineering to develop cancer drugs that improve the lives of patients.

Drive near-term value with lacutamab

Advance our innovative pipeline

Build a sustainable business through partnerships

innate pharma

Our robust pipeline of proprietary & partnered assets

	Program	Target	Indication	Pre-Clinical	Phase 1	Phase 2	Phase 3	Upcoming Milestone
Proprietary	**Lacutamab**	KIR3DL2	Sezary syndrome / MF	TELLOMAK (FDA FAST TRACK/EMA PRIME DESIGNATION)				ASH/ Final data H2 2023
			PTCL	KILT Phase 2 / Phase 1b				IST with LYSA
	IPH5301	CD73	Cancer (solid tumors)	CHANCES				IST with IPC
	IPH6501 ANKET **Others**	CD20 Undisclosed		Phase 1 starting Pre-clinical				IPH6501 Phase 1 start
	IPH45 **IPH43** **Other**	Nectin-4 MICA/B Undisclosed	ADC	Pre-clinical				
Partnered	**Monalizumab** AstraZeneca	NKG2A	Unresectable Stg III NSCLC	PACIFIC-9				Data readout > 2024
			Neoadjuvant NSCLC	NeoCOAST-2				Data readout > 2024
	IPH5201 AstraZeneca	CD39	Neoadjuvant NSCLC	MATISSE				
	SAR443579 / IPH6101 ANKET **SAR'514 / IPH6401** **IPH62** sanofi **2 options**	CD123 BCMA B7-H3 Undisclosed	R/R AML, B-ALL, HR-MDS R/R MM, LCA	PHASE 1 / 2 PHASE 1 / 2 Research				ASH 2023
	Other Takeda	Undisclosed	ADC Celiac disease	Pre-clinical				

ADC: antibody drug conjugate; MF: Mycosis Fungoides ; PTCL: Peripheral T Cell Lymphoma; NSCLC: Non-small cell lung cancer; AML: Acute Myeloid Leukemia; B-ALL: B-cell Acute Lymphoblastic Leukemia; HR-MDS: High Risk-myelodysplasia; MM: Multiple Myeloma; LCA: Light-chain Amyloidosis; IST: investigator-sponsored study; IND: Investigational new drug

Lacutamab | Development strategy

A potential new standard of care in the T-cell lymphomas expressing KIR3DL2

Cutaneous T cell lymphoma

Sézary syndrome

80-200 patients
~90% KIR3DL2 expression

Mycosis fungoides

2,200-4,400 patients
~50% KIR3DL2 expression

TELLOMAK

Phase 2 Trial

Sézary syndrome

Cohort 1 (N~60)

Minimum of 2 prior therapies, including mogamulizumab

Mycosis fungoides

3 cohorts (N~100)

Cohort 2	Cohort 3	Cohort 4 All comers
KIR3DL2 +	KIR3DL2 -	KIR3DL2 +/-

At least 2 prior systemic therapies

- Sézary syndrome Phase 2 Final data ASH 2023
- Mycosis fungoides Phase 2 Final data H2 2023

Peripheral T cell lymphoma

~18,000 patients
~50% KIR3DL2 expression

Phase 1b/2 Trials

Phase 1b trial

monotherapy

KILT Phase 2 trial

combination with GEMOX chemotherapy (gemcitabine in combination with oxaliplatin) versus GEMOX alone

- Preliminary data ASH 2023

ASH 2023 abstract - Lacutamab Sézary syndrome Phase 2 data

Lacutamab in Patients with Relapsed and Refractory Sézary Syndrome: Results from the TELLOMAK Phase 2 Trial

185 Lacutamab in Patients with Relapsed and Refractory Sézary Syndrome: Results from the Tellomak Phase 2 Trial

Program: Oral and Poster Abstracts
Type: Oral
Session: 624. Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological: Topics in T Cell, Szary and Hodgkin Lymphomas
Hematology Disease Topics & Pathways:
Research, clinical trials, adult, Lymphomas, Clinical Research, T Cell lymphoma, drug development, Diseases, Therapies, Lymphoid Malignancies, Study Population, Human

Saturday, December 9, 2023: 3:00 PM

Figure 1: Best Global Resposne



Patient baseline characteristics

56 post mogamulizumab patients with advanced, highly refractory and heavily pre-treated disease

6 median lines of prior therapy

14.4 months median follow up

Efficacy results

Clinical Benefit Rate	**87.5%**
Global confirmed ORR	**37.5%**
Skin confirmed ORR	**46.4%**
Blood confirmed ORR	**48.2%**
mPFS	**8.0m**

ASH 2023 abstract: 624, ORR: objective response rate, mPFS: medial progression-free survival

Monalizumab development in progress of Phases 2 and 3 trials

Covering early stages of lung cancer

Stages of the disease

NSCLC Stages I - III resectable

NeoCOAST*

30% major pathological response vs. 11% durvalumab.

Data presented: 2022

AACR American Association for Cancer Research

ESMO congress

Trial in Progress

2023 ASCO ANNUAL MEETING

NeoCOAST-2*

PHASE 2

Patients with Stage II to IIIB NSCLC

Monalizumab + durvalumab + chemotherapy

210 patients (multiple arms)

NSCLC Stage III unresectable

COAST*

~ 60% reduction in the risk of disease progression vs. durvalumab.

~ 15 months average duration of progression-free survival.

Data presented: 2021

ESMO congress

Posted in: April 2022

Journal of Clinical Oncology

Trial in Progress

2023 ASCO ANNUAL MEETING

PACIFIC-9*

PHASE 3

Patients with Stage III unresectable NSCLC

Monalizumab + durvalumab

999 patients (3 arms)

* Study run by AstraZeneca

innate pharma

ANKET®
Antibody-based NK cell Engager Therapeutics

Proprietary NK cell engager platform

Harnesses NK cell effector functions against cancer cells, through the most conserved activating receptor on NK cells: NKp46.

Provides proliferation and activation signals targeted to NK cells.

Demonstrates better anti-tumor efficacy than approved benchmark antibodies in preclinical tumor models.





A versatile, **fit-for-purpose technology** that is creating an entirely new class of tri- and tetra-specific molecules to induce synthetic immunity against cancer.

ANKET® NK cell engager molecules have the potential to strongly control tumor proliferation via the harnessing of NK cells

Growing clinical pipeline

SAR443579 / IPH6101 (CD123)	sanofi	Phase 1 / 2
SAR'514 / IPH6401 (BCMA)	sanofi	Phase 1 / 2
IPH6501 (CD20)	innate	Phase 1 start
IPH62 (B7-H3)	sanofi	Research
2 options	sanofi	Research
Multiple Targets	innate	Research

ANKET®
Antibody-based NK cell Engager Therapeutics

Differentiated MoA

ANKET3

Nature Biotechnology
January 2023



ANKET4

Cell reports medicine
October 2022



ASH 2022 abstract: 4486, 3329, Antibody-Based NK Cell Engager Therapeutics

SAR443579 / IPH6101 promising preliminary single agent clinical activity in R/R AML

SAR443579 / IPH6101 is a trifunctional anti-CD123 NKp46xCD16 NK cell engager

PHASE 1 / 2 underway

82 patients to be enrolled with various hematological malignancies (R/R AML, B-cell ALL or HR MDS)

ASH 2023 Abstract

43 patients (42 R/R AML and 1 HR-MDS)
Well tolerated up to 6 mg/kg QW
Median of 2.0 (1.0 – 10.0) **prior lines of treatment**

Observed clinical benefit: In DLs with a highest dose of 1mg/kg QW, **5/15 (33.3%) AML patients achieved a CR (4 CR / 1 CRi)***

3474 First-in-Human Study of the CD123 NK Cell Engager SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia or High Risk-Myelodysplasia: Updated Safety, Efficacy, Pharmacokinetics and Pharmacodynamics

Program: Oral and Poster Abstracts
Session: 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster II
Hematology Disease Topics & Pathways:
drug development, Therapies, Adverse Events, Study Population, Human

Sunday, December 10, 2023, 6:00 PM-8:00 PM

ESMO presentation (data cut-off: Aug 7, 2023)

Two responders remain in remission
after 8.8 and 12.2 months of treatment



sanofi

MADRID 2023 ESMO congress

SAR443579/IPH6101 received Fast Track Designation for the treatment of hematologic malignancies

*data cut off: Juy 5, 2023 CR: complete remission; Cri: CR with incomplete hematological recovery; DL: dose level, AML: acute myeloid leukemia, HR MDS: higher-risk myelodysplastic syndrome, DL: dose level, ASH 2023 abstract 704

sanofi

Strategic partnership between Sanofi and Innate

Three molecules licensed to Sanofi plus two undisclosed targets under options

Ongoing programs

- **SAR'579 / IPH6101** — ANKET® — CD123 — Phase 1 / 2 in AML
- **SAR'514 / IPH6401** — ANKET® x CROSSODILE® platform — BCMA — Phase 1 / 2 in Multiple Myeloma
- **IPH62** — ANKET® — B7-H3 — Research
- **OPTION** — ANKET® — 2 undisclosed targets

Payments received

- €16m
- €25m upfront

2022 expansion

Total amount of the agreement

€1.75 Bn
+ Royalties on net sales

Sanofi is responsible for the clinical development, manufacturing and commercialization of products resulting from the research collaboration

innate pharma

Our antibody platform contributes to the R&D engine with novel assets under Antibody Drug Conjugates formats

ADC Research pipeline – Lead asset at pre-IND stage

IPH45 (Nectin-4)	innate	Pre-IND
IPH43 (MICA)	innate	Research
Target (Tumor antigen)	innate	Research
Target (Coeliac disease)	Takeda	Research



IPH45 (Nectin-4)

A next generation ADC to maximize the Nectin-4 opportunity across multiple tumor types

IPH45 key scientific characteristics

- Differentiated epitope non-competing with EV
- Stable linker with high hydrophilicity
- Topo I payload more potent than DxD

Translate into differentiated features

- Larger therapeutic index than EV
- Longer PK than EV
- Bystander effect
- Efficacy in EV-resistant models

IPH45 overcomes resistance to EV in preclinical models



Potential to maximize the Nectin-4 opportunity

Address relapsed or refractory **EV/MMAE-treated patients** + Address multiple tumor types across **various Nectin-4 expression levels** + Potential for **improved dosing regimen** and **better safety**

EV: Enfortumab vedotin, MMAE: Monomethyl auristatin E

Presentations at the ASH 2023 Annual Meeting



What will be presented?

- Lacutamab Phase 2 Sézay syndrome
- Lacutamab Phase 1b PTCL initial data
- SAR443579 (CD123 ANKET) (Sanofi)

Innate Pharma lacutamab KOL analyst & investor call December TBC - San Diego

Newsflow and upcoming catalysts

Delivering across our strategic objectives

2023 ASCO ANNUAL MEETING

EHA EUROPEAN HEMATOLOGY ASSOCIATION

- SAR'579 / IPH6101 ANKET® (CD123) | Phase 1 (Sanofi)
- SAR'514 / IPH6401 ANKET® (BCMA) | Phase 1 (Sanofi)
- IPH6501 ANKET® (CD20) | Phase 1 start

- Lacutamab Phase 2 TELLOMAK | Final data SS & MF
- Lacutamab Phase 1b PTCL | preliminary data

- Monalizumab PACIFIC-9 | Phase 3 readout (AZ)
- Monalizumab NeoCOAST-2 | Phase 2 readout (AZ)
- IPH5201(CD39) MATISSE | Phase 2 readout (AZ)

- SAR'579 / IPH6101 ANKET® (CD123) | Next steps (Sanofi)
- SAR'514 / IPH6401 ANKET® (BCMA) | Next steps (Sanofi)
- IPH62 ANKET® (B7-H3) | Next Steps (Sanofi)
- 2 ANKET options | (Sanofi)
- IPH6501 ANKET® (CD20) | Phase 1 data
- IPH45 ADC (Nectin-4) | Phase 1 start

- Lacutamab CTCL | Next steps
- Lacutamab Phase 1b PTCL | Final data

2023 **2024+**

Key Takeaways

Create value for patients and shareholders

Strategic Priorities

Early R&D focus to drive value through later stage partnerships

Robust pipeline of Antibody engineering capabilities

- Advancing lacutamab
- Maximizing ANKET® platform
- Continuing to explore ADC

Track record of strategic partnerships

AstraZeneca (monalizumab, IPH5201), Sanofi (SAR443579 / IPH6101, SAR'514 / IPH6401, IPH62, 2 options), Takeda (ADC)

Strong cash position

- €121.9m* as of September 30, 2023
- Sufficient to fund operations into H2 2025

*Including short term investments (€22.0m) and non-current financial instruments (€32.2m)



innate pharma

Thank you

www.innate-pharma.com
investors@innate-pharma.fr

EURONEXT : IPH.PA NASDAQ : IPHA